Vitamin B2 (Riboflavin) and Dementia Risk Reduction

Evidence on B Vitamins and Dementia

The European Society for Clinical Nutrition and Metabolism (ESPEN) recommends against B vitamin supplementation for prevention or correction of cognitive decline in persons with dementia when there is no indication of deficiency, with a Grade of evidence: low 1, 2, 3
Multiple randomized controlled trials and systematic reviews found no consistent benefit of B vitamin supplementation on cognition, as stated by ESPEN 1, 3
The 2024 updated ESPEN guideline states that no controlled intervention study has demonstrated a cognitive benefit for persons with dementia from supplementing a single nutrient, including folic acid, vitamin B, B12, D, E, or selenium 4

Specific evidence regarding vitamin B2 (riboflavin) and dementia is limited, with most studies focusing on vitamin B6, B12, and folate 3, 5
Supplementation with B vitamins reduces homocysteine levels, a potential risk factor for dementia, but this biochemical effect has not translated to meaningful cognitive benefits in clinical trials 3, 6
A Cochrane review found no evidence that B vitamin supplementation improves dementia or slows cognitive decline in subjects without vitamin deficiency 1, 7

B vitamin supplementation, including riboflavin, should be considered only when there is a documented deficiency, as recommended by ESPEN 1, 4
Existing deficiencies should be corrected with adequate supplementation, regardless of dementia status, according to the 2024 ESPEN guideline 4
Normal doses, not mega-doses, should be used when supplementation is indicated to avoid potential toxic effects, as stated by ESPEN 4

Current clinical guidelines do not support B vitamin supplementation for dementia prevention or treatment in the absence of deficiency, as stated by ESPEN 1, 4
For patients concerned about dementia risk, focus should be placed on overall dietary quality rather than single nutrient supplementation, according to the 2024 ESPEN guideline 4
If considering B vitamin supplementation, priority should be given to patients with documented deficiencies or those at high risk for deficiency, as recommended by ESPEN 4